RT Journal Article
SR Electronic
T1 Retinal BioAge Reveals Indicators of Cardiovascular-Kidney-Metabolic Syndrome in US and UK Populations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.18.24310670
DO 10.1101/2024.07.18.24310670
A1 Vaghefi, Ehsan
A1 An, Songyang
A1 Moghadam, Shima
A1 Yang, Song
A1 Xie, Li
A1 Durbin, Mary K.
A1 Hou, Huiyuan
A1 Weinreb, Robert N.
A1 Squirrell, David
A1 McConnell, Michael V.
YR 2024
UL http://medrxiv.org/content/early/2024/07/19/2024.07.18.24310670.abstract
AB Background There is a growing recognition of the divergence between biological and chronological age, as well as the interaction among cardiovascular, kidney, and metabolic (CKM) diseases, known as CKM syndrome, in shortening both lifespan and healthspan. Detecting indicators of CKM syndrome can prompt lifestyle and risk-factor management to prevent progression to adverse clinical events. In this study, we tested a novel deep-learning model, retinal BioAge, to determine whether it could identify individuals with a higher prevalence of CKM indicators compared to their peers of similar chronological age.Methods Retinal images and health records were analyzed from both the UK Biobank population health study and the US-based EyePACS 10K dataset of persons living with diabetes. 77,887 retinal images from 44,731 unique participants were used to train the retinal BioAge model. For validation, separate test sets of 10,976 images (5,476 individuals) from UK Biobank and 19,856 retinal images (9,786 individuals) from EyePACS 10K were analyzed. Retinal AgeGap (retinal BioAge – chronological age) was calculated for each participant, and those in the top and bottom retinal AgeGap quartiles were compared for prevalence of abnormal blood pressure, cholesterol, kidney function, and hemoglobin A1c.Results In UK Biobank, participants in the top retinal AgeGap quartile had significantly higher prevalence of hypertension compared to the bottom quartile (36.3% vs. 29.0%, p<0.001), while the prevalence was similar for elevated non-HDL cholesterol (77.9% vs. 78.4%, p=0.80), impaired kidney function (4.8% vs. 4.2%, p=0.60), and diabetes (3.1% vs. 2.2%, p=0.24). In contrast, EyePACS 10K individuals in the top retinal AgeGap quartile had higher prevalence of elevated non-HDL cholesterol (49.9% vs. 43.0%, p<0.001), impaired kidney function (36.7% vs. 23.1%, p<0.001), suboptimally controlled diabetes (76.5% vs. 60.0%, p<0.001), and diabetic retinopathy (52.9% vs. 8.0%, p<0.001), but not hypertension (53.8% vs. 55.4%, p=0.33).Conclusion A deep-learning retinal BioAge model identified individuals who had a higher prevalence of underlying indicators of CKM syndrome compared to their peers, particularly in a diverse US dataset of persons living with diabetes.What Is New?Accelerated biological aging predicted by a novel deep-learning analysis of standard retinal images was able to detect multiple indicators of the new cardiovascular-kidney-metabolic syndrome in US and UK populations.What Are the Clinical Implications?Rapid, point-of-care analysis of images from routine eye exams can broaden access to the detection and awareness of adverse cardiovascular, kidney, and metabolic health.With the broad range of prevention interventions to reduce progression of cardiovascular-kidney-metabolic syndrome, earlier and broader detection is important to improve public health outcomes.Competing Interest StatementEV, SA, SM, SY, LX, DS, and MVM report employment by Toku Eyes. MVM reports compensation by Porter Health for consultant services. MKD and HH report employment by Topcon Healthcare. RNW reports compensation by Toku Eyes for consultant and board of directors services and by Topcon Healthcare for consultant services, as well as research instruments from Topcon, Visionix, Centervue, and Konan.Clinical TrialThis was not a prospective clinical trial.Funding StatementToku EyesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank (IRB UOA-86299) EyePACS 10K (IRB UCB 2017-09-10340)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets from UK Biobank and EyePACS are available through those organizations.